The lympho-hematopoietic colony-forming assay has been redesigned into a rapid, nonsubjective and standardized proliferation assay that can measure the effects of compounds on multiple stem and progenitor cell populations from different species simultaneously using a sensitive, high-throughput bioluminescence readout. Eleven reference compounds from the Registry of Cytotoxicity (RC) and eight other compounds, including anticancer drugs, were studied over an 8-to 9-log dose range for their effects on seven cell populations from both human and mouse bone marrow simultaneously. The cell populations studied included a primitive (HPP-SP) and mature (CFC-GEMM) stem cell, three hematopoietic (BFU-E, GM-CFC, Mk-CFC) and two lymphopoietic (T-CFC, B-CFC) populations. The results reveal a five-point prediction paradigm for lympho-hematotoxicity. Depending on how and which populations are affected, the resulting effects in the periphery can be predicted. Validation against the RC Prediction Model produces a high degree of correlation between the in vitro IC 50 values and known in vivo LD 50 values, thereby allowing preclinical dosing to be predicted. If primary human hematopoietic target tissue is used, inhibitory concentration (IC 50 /IC 75 /IC 90 ) values of anticancer and other drugs can be converted into predicted clinical doses which, when compared to published chemotherapeutic dosing regimen, are very similar. When performed during early drug screening, the prediction value of the assay should help reduce time and cost, but above all, provide increase efficacy and safety for the patient.
The primary causes of drug failure are lack of efficacy and toxicity. Despite new technologies that have emerged in recent years that could predict toxicity in patients, either there has been an unwillingness to incorporate these new technologies early in the drug development pipeline, or they are not being used to their full advantage, incorporated too late or not at all.
Although toxicity studies performed during late screening and lead optimization may shed light on potential problems to the blood-forming system, conventional hemotoxicity testing is performed only during preclinical animal testing. It is part of a large number of tests and usually consists of measuring peripheral blood cell parameters and pathological effects in the hematopoietic organs. These are certainly important parameters, but they have little, if any, predictive value. Serious toxic side effects observed during preclinical testing, or even worse, during clinical trials cost not only time and money, but potential danger to the patients. Bradley and Metcalf (1966) and Pluznik and Saks (1966) introduced the hematopoietic colony-forming assays (CFA). These in vitro assays detect clonal expansion of stem, progenitor, and precursor cells. This methodology has been part of the experimental and clinical hematology community for nearly four decades and has been validated worldwide. Without these assays, the biology and physiology of the blood-forming system and the lympho-hematopoietic hierarchy as we know it today, would not have been possible. Differentiation of various cell populations in vitro is made possible by the functional ability of these cells to proliferate, divide, and differentiate, in response to growth factors, into cells that are immobilized in a semisolid medium to form colonies that can be viewed and counted under the microscope. There is no other assay system that can detect and measure the different cell populations that comprise the stem cell and amplification compartments of the lympho-hematopoietic system. It is important to emphasize that the CFA is a differentiation assay; that is, it measures the capacity of cells to form colonies of differentiated cells in vitro. There are many reports using the colony-forming assays in drug development Parchment, 1998) and environmental studies (Parent-Massin et al., 1993; Van Den Heuvel et al., 2001) , but with few exceptions, it has never been used routinely, despite the fact that it can provide greater predictive information regarding compound toxicity than conventional hemotoxicity . There are, however, a number of drawbacks to the CFA that have hindered its use in drug development. First, it is time consuming to perform. Manual enumeration of colonies is highly subjective and requires technical expertise. Furthermore, colony enumeration lacks standardization. Although side-by-side cell populations and species comparisons can be performed, this can only be done on a small scale, due to the low throughput capability of the system. This almost precludes the use of the assay during the drug development process, except where a drug is known to interfere with the differentiation process. These are usually relatively small studies, since the assay is limited by the manual enumeration process.
Realizing that no other assay system can be used to detect and measure different proliferating cell populations, the colony-forming assay methodology was redesigned into an ATP-based bioluminescence proliferation assay readout. The new assay is called HALO (Hemotoxicity Assays via Luminescence Output). HALO does not suffer from the drawbacks of the manual CFA. It is rapid, being completed in half the time of the manual CFA, highly sensitive, nonsubjective, and standardized. The 96-well plate format provides high-throughput capability. In addition, the system provides multifunctional capability so that up to 14 different lympho-hematopoietic populations from different hematopoietic sources (peripheral blood and bone marrow and cord blood from humans) from five different species (human, nonhuman primate, dog, rat, and mouse) can be detected and measured simultaneously. The HALO Platform has been validated against the manual CFA (Rich and Hall, submitted for publication).
As part of a further validation study, 11 reference compounds from the Registry of Cytotoxicity (RC) (NIH Publication, 2001) were tested on seven different lympho-hematopoietic cell populations from fresh human and mouse bone marrow. These results, together with those obtained from a number of different anticancer drugs tested on fresh human bone marrow, have provided evidence for a new prediction hemotoxicity paradigm that allows the assay system to be used during the early screening stages of drug development. This report describes the predictions and examples that make up this paradigm. In addition, validation of HALO against the Registry of Cytotoxicity Prediction Model allows the estimation of relevant starting doses for preclinical studies and even initial or clinically relevant dosing for clinical trials (NIH Publication, 2001; Spielmann et al., 1999) .
MATERIALS AND METHODS
Drugs and compounds. All drugs and compounds used, except where indicated, were obtained from Sigma Chemicals (St. Louis, MO) and were tested over an 8-to 9-log dose range, from 1 pM to 10 lM or 0.1 mM. Except where drugs or compounds were soluble in aqueous medium, DMSO was used as the solvent. All further dilutions were performed in 100% fetal bovine serum. Each dilution was added to replicate wells at a volume of 10% of the total culture well volume of 100 ll.
Tissues used and their preparation. Fresh primary whole bone marrow was obtained from normal donors and purchased from Cambrex BioSciences (Walkserville, MD) after they had signed a consent form approved by the Internal Review Board (IRB). Approval to use this tissue was also obtained from the Dorn Veteran Affairs Medical Center (Columbia, SC) and the BioMed IRB (San Diego, CA). The mononuclear cell (MNC) fraction was separated by density gradient centrifugation using NycoPrep 1.077 (Greiner BioOne, Longwood, FL). After washing once in phosphate-buffered saline (PBS), the cells were resuspended in Iscove's Modified Dulbecco's Medium (IMDM). Viability was detected by 7-aminoactinomycin D (7-AAD, Beckman Coulter, Miami, FL) using flow cytometry, and nucleated cell counts (Z2 Particle Analyzer, Beckman Coulter) were performed on the whole tissue and after resuspension of separated MNCs.
Use of mice for this study was approved after submission of an animal use protocol to Colorado State University, Ft. Collins, CO, from which the animals were obtained. Mouse bone marrow was obtained from C57Bl/6J female mice 10-12 weeks old. After removing the femora, the bone marrow was flushed into IMDM according the procedure described previously (Rich and Kubanek, 1982) .
Growth factors and cell populations. Human growth factors, with the exception of erythropoietin (EPO), which was obtained from R&D Systems (Minneapolis, MN), were obtained from CellGenix, Inc (Gaithersburg, MD). Murine growth factors were obtained from R&D Systems. Stimulation of different cell populations used the following growth factor combinations. Highproliferative-potential stem and progenitor cells (HPP-SP; stem cell factor (SCF, 50 ng/ml), interleukin-3 (IL-3, 100 ng/ml), interleukin-6 (IL-6, 20 ng/ml), Flt3-ligand (50 ng/ml), colony-forming cell granulocyte, erythroid, macrophage, megakaryocyte (CFC-GEMM): Erythropoietin (EPO, 3U/ml), granulocytemacrophage colony-stimulating factor (GM-CSF, 20 ng/ml), granulocyte colony-stimulating factor (G-CSF, 20 ng/ml), thrombopoietin (TPO, 30 ng/ml), IL-3 (10 ng/ml), IL-6, SCF, Flt3-L. Burst-forming unit-erythroid (BFU-E): EPO, IL-3 and SCF. Granulocyte-macrophage colony-forming cells (GM-CFC): GM-CSF, IL-3, SCF. Megakaryocyte colony-forming cell (Mk-CFC): TPO and SCF. T-lymphocyte colony-forming cells (T-CFC): interleukin-2 (IL-2, 50 ng/ml). B-lymphocyte colony-forming cell (B-CFC): interleukin-7 (IL-7, 20 ng/ml). Murine CFC-GEMM did contain G-CSF.
The seven-population prediction hemotoxicity paradigm (7-PPHP). The HALO Platform (HemoGenix, Inc, Colorado Springs, CO) was used to detect and measure the seven populations described above, namely two stem cells (HPP-SP and CFC-GEMM), three hematopoietic progenitor cells (BFU-E, GM-CFC, Mk-CFC), and two lymphopoietic populations (T-CFC and B-CFC). The HALO 7-PPHP was performed by mixing three separate HALO reagent mixes consisting of a serum mix (four parts), a methyl cellulose mix (four parts), and a growth factor mix (one part) with the bone marrow target cells (one part) to form a master mix. The cell density used was 1.5 3 10 6 /ml. One hundred ll of the master mix was dispensed into wells of a 96-well, whitewalled, transparent bottom luminescence plate (Greiner BioOne, Longwood, FL) where the compound dose had been added to eight replicates. The 96-well plates were placed in a humidified incubator (Heraeus, Kendro Scientific Instruments, Ashville, NC) at 37°C containing an atmosphere of 5% CO 2 and 5% O 2 (Rich, 1986; Rich and Kubanek, 1982) . Mouse cells were incubated for 5 days, while human cells were incubated for 7 days.
Controls. For each compound and for each cell population tested, four controls were included. These were: (a) spontaneous control which contained cells without growth factors or drug/compound addition, (b) vehicle-only control, (c) growth factor control, (d) growth-factor-plus-vehicle control.
Measurement of luminescence. The proliferative status in control and drug-treated cells is dependent on the intracellular ATP concentration. As the cells proliferate or when the cells are inhibited, the proportion of intracellular ATP varies accordingly. Using a multichannel pipette or liquid handler (Beckman Coulter, BioMek 2000) , 50 ll of an ATP-releasing reagent (ATP-RR) was added and thoroughly mixed with the contents of each well. The plates 428 RICH AND HALL were incubated at 23°C for 15 min, during which time the intracellular ATP was released from the cultured cells. Thereafter, 100 ll of luminescence monitoring reagent (ATP-MR) was added to each well and mixed. The plates were then transferred to a plate luminometer (Molecular Devices, Lmax) and the bioluminescence measured.
Prior to all sample measurements, a background and ATP standard curve was performed. The background consisted of 100 ll of medium (IMDM) added to four replicate wells followed by the addition of ATP-RR and ATP-MR. The ATP standard dose response was performed by serially diluting ATP to 1 lM, 0.5 lM, 0.1 lM, 0.05 lM, and 0.01 lM and dispensing each dilution into four replicate wells followed by the addition of ATP-RR and ATP-MR. Performing an ATP standard dose response ensured that the luminometer was working correctly and that the luminescence reagents were functional. In addition, it allows conversion of nonstandardized Relative Luminescence Units (RLU) into standardized ATP (lM) unit values, so that luminescence measured on different instruments can be compared. Another advantage of performing the ATP dose response is that results can be normalized so that experiments performed at different times and even in different laboratories can be compared.
Statistics. Luminescence results were obtained using Softmax software (Molecular Devices). The software was programmed so that the background ATP value was subtracted from all raw data and converted directly to ATP (lM) values using the ATP standard dose response curve. The mean RLU and ATP values, standard deviation and percent variation coefficient were calculated. Results are expressed as the mean RLU-background/well or mean normalized ATP (lM) production/well. Where possible, the inhibitory concentrations at 50% (IC 50 values) were estimated from the dose response curves using a nonlinear, Hill or four-parameter logistic analysis regression. To calculate the IC 75 or IC 90 values, the RLU or ATP results were converted to percent from the growth-factor-plus-vehicle control. Nonlinear curve-fitting analysis was performed, and the IC values estimated using TableCurve 2D software (SPSS, Inc). Linear regression analysis and correlation was performed to compare results obtained from HALO with those of the registry of Cytotoxicity. Results were compared using analysis of variance (ANOVA). Table 1 shows the results of the initial 11 RC reference compounds tested on 7 populations from both human and mouse bone marrow. The IC 50 values derived from the RC list are shown. There are several important aspects of this table that should be emphasized. First, the IC 50 values, calculated from the dose response curves for individual lympho-hematopoietic cell populations from either mouse or human bone marrow that correspond to approximately the same IC 50 values as those from the RC list are shown in bold. The agents demonstrating Note. The IC 50 values obtained by HALO which are similar to those in the Registry are shown in bold. Registry of Cytotoxicity IC 50 values were obtained using a standardized neutral red uptake test on mouse 3T3 and normal human keritinocytes (NHK). In the event that a nonlinear regression could not be fitted to the data, the term ''No fit'' is used. If a compound exhibited a stimulation, this is designated in the table as ''þve,'' and a nonlinear regression fit could not be performed. All IC 50 values are presented in mM except where indicated. PREDICTIVE HEMOTOXICOLOGY PARADIGM these values include cadmium chloride, ibuprofen, propanolol hydrochloride, and sodium dichromate. Second, for these compounds there are differences not only between the two species, but also between the IC 50 values for different populations. Thus, even though differences between species would be expected, differences between cell populations were obtained. Third, in some cases, no IC 50 values could be estimated, because the compound exhibited no effect over the dose range tested. For the compounds antipyrine and naladixic acid no effect was observed on any of the seven populations from either species. Fourth, in other cases, the IC 50 values were different from those derived from the RC list. These included N,N-dimethylformamide, glycerol, p-phenelenediamine, and salicylic acid. Finally, in many cases, relying just on the IC 50 value may result in information being overlooked. The form of the dose response can provide a valuable insight into the cellular response. Thus, a positive response over the whole or part of the dose range was observed for some of the populations. Examples of this were for murine HPP-SP and T-CFC response to N,N-dimethylformamide and the positive responses of human HPP-SP, CFC-GEMM, and BFU-E to salycilic acid. Table 2 depicts the results from eight compounds tested on primary human bone marrow alone. In this case, where possible, the IC 50 , IC 75 , and IC 90 values were estimated. The drugs 5-FU, busulfan, chloramphenicol, and doxorubicin were also part of the RC list, and some, but not all, of the IC 50 values from the seven lympho-hematopoietic populations tested correspond to those in the RC. Once again, the difference in population sensitivities is a clear indication that toxicity (or lack of toxicity) to one population may not be representative of all populations. In some cases, there was no effect on one or more of the seven proliferative populations tested, as seen for hydroxyurea. For chloramphenicol, there was a stimulation of HPP-SP, but the most pronounced effect was the specific reduction in BFU-E.
RESULTS
From the pattern of the dose responses obtained for each of the seven cell populations measured, it was possible to discern several commonalities which can be summarized into five predictions. Taken together, the effect of virtually any compound on the maturing and end cell populations detected in the periphery can be predicted, thereby providing valuable information for preclinical and phase I/II clinical human trials prior to the onset of these studies. The five predictions are summarized as follows. 
Note. A further eight compounds, six of which are anticancer drugs, were tested using the HALO 7-population platform, and the IC 50 values obtained (where applicable) compared to those in the Registry of Cytotoxicity. Those values in the same order of magnitude, obtained from both systems, are shown in bold. Where a nonlinear regression could not be fitted, the term ''No fit'' is used. 
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Prediction 1
If no demonstrable affect occurs at the stem or on any of the proliferating progenitor or precursor cell populations, the compound will have no affect on lympho-hematopoiesis. This, however, does not exclude the possibility that the compound acts on nonproliferating or maturing cells or end cells, since HALO would not detect changes in this part of the system. In this latter case, the classical colony-forming assay would have to be employed. Both naladixic acid and antipyrine are examples of this first prediction.
Prediction 2
If a compound acts on one or more lineages of the amplification and differentiation compartment, which includes all progenitor and precursor cells, the corresponding mature functional cells would be affected. Figures 1A-1C demonstrate this prediction using chloramphenicol. Figure 1A shows the effect on the human primitive and mature stem cell populations. Figure 1B shows the effect on the three hematopoietic progenitor populations, and Figure 1C shows the effect on the two lymphopoietic cell populations. It is first interesting to note that the primitive stem cell population, HPP-SP, exhibits a positive effect over the complete dose range to chloramphenicol. This positive effect is responsible for the partial stimulation in both the lymphopoietic populations. This specific effect, where the response of the HPP-SP population can lead to a concomitant response of the lymphopoietic cell populations is also described in Prediction 5 below. As far as the present prediction is concerned, there is no affect on the CFC-GEMM, GM-CFC, or Mk-CFC, but a specific inhibition is observed for the BFU-E population. The BFU-E, GM-CFC, and Mk-CFC are part of the hematopoietic amplification and differentiation compartment. Since only the BFU-E is inhibited, the prediction would be that depletion in erythrocytes would result, leading to an anemic situation. Indeed, the specific and reversible inhibition of chloramphenicol and thiamphenicol on in vitro erythropoiesis has been studied previously (Nijhof et al., 1977) , but chloramphenicol toxicity and its role in the induction of aplastic anemia have been known for decades.
Prediction 3
If a compound acts at the mature stem cell level (CFC-GEMM), then only the hematopoietic lineages (not the lymphopoietic lineages) will be affected. Benzene is an example (Figs.  2A-2C ) of this prediction, but as in the case of Prediction 2, other effects are observed. In this case, there is an inhibition of the T-CFC population, but no curve fit could be obtained for the B-CFC. Unlike chloramphenicol, the HPP-SP population exhibits an apparent stimulation at low benzene doses followed by a plateau to the highest dose measured. The inhibition observed on T-CFC (Li et al., 1996) by benzene would therefore be included in Prediction 2. The present prediction indicates that, if an affect on the CFC-GEMM occurs, the hematopoietic lineages will also be affected. In this particular case, however, only the BFU-E (Seidel et al., 1991) and GM-CFC populations are inhibited, whereas the Mk-CFC remained unchanged. Thus, the prediction would be that an anemia and neutropenia would result. This is indeed the case, since benzene has been shown to induce aplastic anemia (Quitt et al., 2004; Velasco et al., 2001) and neutropenia (Ruiz et al., 1994) .
Prediction 4
If a compound affects both primitive and mature stem cells, then the whole lympho-hematopoietic system will be affected. Of the 11 compounds tested on both human and mouse target cells, three compounds were found to be inhibitory on both the primitive and mature stem cells, resulting in a decrease in all hematopoietic and lymphopoietic lineages. These include cadmium chloride, sodium dichromate, and trichlofon. With the exception of 5-fluorouracil and busulfan, neither of which affected the T-CFC population, doxorubicin, daunorubicin, and Imastinib mesylate were inhibitory on all seven populations. Although graphical examples of all of these compounds could be presented, Figures 3A-3C and 4A-4C show the effect of sodium dichromate and daunorubicin, respectively. However, for all the anticancer drugs, an anemia, neutropenia, and thrombocytopenia would be predicted, which is observed in the clinical situation.
Prediction 5
If the compound acts only on primitive stem cells (HPP-SP), then the cells of the lymphopoietic system will be affected first. Although the HPP-SP population is not the most primitive stem cell, it feeds into both the lymphopoietic and hematopoietic systems. Partial or complete demise of the HPP-SP population could render the system inoperable, since there would be a reduced or complete lack of cells entering the more mature stem cell compartments. If no influx into the CFC-GEMM population occurs, then the rest of the hematopoietic system will run down, and the lympho-hematopoietic system could be eradicated with resulting death. The example of p-phenelediamine (Figs. 5A-5C ), shows the effect of inhibition of the murine HPP-SP population (Fig. 5A ) on both the T-CFC and B-CFC (Fig. 5C ). There is no effect of murine hematopoietic progenitor cells. None of the human cell populations are affected by the compound, thereby illustrating an example of species difference. The present protocol (direct addition of the compound) does not allow the effect on the mature stem cell population with corresponding decreases in the hematopoietic lineages to be observed. However, by default, reduction or eradication of the HPP-SP population and more primitive stem cell populations that feed into the HPP-SP cell pool would eventually result in the CFC-GEMM population being significantly reduced and eradicated and would lead to a situation in 
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RICH AND HALL which the hematopoietic lineages would also be wiped out. Prediction 4 illustrates the effects of a compound when it acts on both HPP-SP and CFC-GEMM simultaneously. It should be pointed out that, whereas daunorubicin (Fig. 4) and many other anticancer drugs specifically inhibit proliferation, other compounds such as sodium dichromate and p-phenelenediamine can act on quiescent cells, making these compounds particularly toxic. Tables 1 and 2) , the IC 50 values obtained using the HALO Platform were plotted against the oral rat or mouse LD 50 values (mmol/kg) provided in the Registry. The IC 50 values listed in the Registry represent a combination of mouse 3T3 cell line and primary human keritinocyte data. The results for cadmium chloride, ibuprofen, propanolol.HCl, sodium dichromate, 5-fluorouracil, busulfan, chloramphenicol, doxorubicin, and daunorubicin (which is not in the RC list), produced a coefficient of correlation, R, of 0.908 (r 2 ¼ 0.825) (Fig. 6) . When the IC 50 values obtained using HALO were correlated with the IC 50 values in the Registry, a coefficient of correlation of 0.973 was obtained. There was no statistical difference between the regression for HALO IC 50 and RC LD 50 and that for RC IC 50 and RC LD 50 values for the agents listed above (p > 0.01). All nine compounds lie within the 95% prediction limits of the statistic. This result has at least three important implications. The first is that the HALO Platform has been validated against reference compounds of the Registry of Cytotoxicity. Second, the RC Prediction Model can be applied to cell systems other than mouse 3T3 and human keritinocytes with an end point other than neutral red. Third, the HALO Platform can be used to calculate animal dosing for preclinical studies and initial or clinically relevant doses for patient clinical trials based on RC Prediction Model. Table 3 shows the CFC-GEMM IC 50 , IC 75 , and IC 90 values for eight anticancer drugs analyzed here and in previous studies using the HALO Platform. The correlation between HALO and the RC Prediction Model allows the regression as expressed by the equation, Log LD 50 ¼ 0.435 3 log (IC 50 ) þ 0.625, to be used (NIH Publication 2001; Spielmann et al., 1999) . For all compounds tested, the LD 50 could be calculated in mM/kg. Multiplying these values by the molecular weight of the compound produced the dose in mg/kg, and by multiplying again by the factor 37 (FDA guidance document, 2002), the predicted clinical dose in mg/m 2 could be calculated. When these values were compared to actual drug doses used in various chemotherapeutic regimen, the doses, with the exception of vinblastine, were either similar or in the same order of magnitude as those calculated from the HALO parameters.
DISCUSSION
The colony-forming assays, first introduced in 1966, provide the only tool capable of detecting and dissecting cell populations of the lympho-hematopoietic system that cannot be morphologically identified. All of the populations in question have the functional ability to proliferate, divide, and differentiate into morphologically recognizable cells, which, if immobilized in semisolid medium (agar or methyl cellulose), produce colonies that can be counted under the microscope. The number of colonies produced is proportional to the number of target cells used, the concentration of growth factors added to stimulate the cells, and if tested, the dose of compound being examined. The colony-forming assays have provided much of the information that has produced our knowledge of the hierarchy, organization, and regulation of the lympho-hematopoietic system as we know it today. No other assay exists to study the functional ability of cells comprising the stem and amplification compartments of the lympho-hematopoietic system.
The colony-forming assays have been used to study the effects of compounds in drug development and in the environmental toxicity arena on specific progenitor cells populations Parchment, 1998; Parent-Massin et al., 1993; Van Den Heuvel et al., 2001) . However, the European Center for Validation of Alternative Methods (ECVAM) has promoted and paved the way for routine and regulatory aspects using this assay technique in a standardized manner (Gribaldo, 2002; Gribaldo et al., 1996; NIH Publication, 2001 ). Much of this work has focused on drug-induce neutropenia using the GM-CFC assay (Pessina et al., 2001) , and an international blind trial was carried out to validate a prediction model (Pessina et al., 2003) . This work demonstrated that an 87% prediction of the maximum tolerated dose (MTD) could be achieved when the IC 90 value of the compound was determined. This was the reason for including the IC 90 values in the studies reported above. Further studies have included other hematopoietic populations such as the Mk-CFC and the BFU-E (Parent-Massin, 2001). A methyl cellulose microculture system for GM-CFC to assess drug-induced toxicity has also been reported (Pessina et al., 2004) . The latter report also tested whether the optical density, using an MTT test, could be used instead of colony counts, but results were not comparable. A MTT test for GM-CFC was reported in 2000 by Horowitz and King using agar as the semi-solid medium rather than methyl cellulose (Horowitz and King, 2000) . More recently, Greenwalt and colleagues (2001) reported on a high-throughput assay for hematopoietic progenitor cells using a fluorescence-based signal detection system.
The manual colony-forming assay is useful if a compound acts specifically at the differentiation or maturation level. That is, the compound acts to block or inhibit differentiation and/or maturation, since the type (and possibly size) of the colonies produced can indicate the stage of differentiation and/or maturation at which this occurs. Furthermore, limiting the testing protocol to a single lineage (e.g., GM-CFC or MK-CFC or BFU-E) limits the information obtained, since although some compounds will act specifically on a particular lineage (e.g., chloramphenicol, phenylhydrazine), the majority will PREDICTIVE HEMOTOXICOLOGY PARADIGM 435 not. If two or more lineages are affected by the same compound, then according to the lympho-hematopoietic hierarchy, that compound must act on the cell(s) that is responsible for producing cells that enter these lineages. Thus, the compound must act at the stem cell level. Therefore, a compound tested on the CFC-GEMM population will provide information relevant to the whole of the hematopoietic system. Similarly, a compound tested on a primitive stem cell population (HPP-SP) capable of producing both lymphopoietic and hematopoietic stem cells will provide information relevant to the whole lympho-hematopoietic system. It therefore follows that, by screening compounds for their effects on the CFC-GEMM and/or HPP-SP population, a wealth of predictive information can be obtained (unpublished results). The CFA procedure can certainly be used to asses the effects of compounds on both the CFC-GEMM and HPP-SP populations, but its use in compound/drug screening is limited. The assay is time-consuming and requires a high degree of technical skill to count and differentiate colonies manually. It is subjective and cannot be standardized. Although multiple populations and multiple species can be compared, the studies demonstrated in this report would be impossible to perform. These drawbacks of the manual clonogenic assay procedure led to the development of the HALO Platform and the use of a highly sensitive bioluminescence signal with high-throughput capability to measure the proliferative capacity of different cell populations from different sources and species simultaneously. Since HALO is based on the methyl cellulose colony-forming assay, it was first validated against the classical assay (Rich and Hall, submitted for publication). To be used for screening compounds, it was necessary to revalidate HALO against a different cytotoxicity test system that had been used to study a number of varied compounds.
Two standard tests for basal cytotoxicity measure the effect of neutral red uptake on the mouse fibroblast 3T3 A31 cell line and normal human keritinocytes (NHK). The Registry of Cytotoxicity (RC) (Halle, 1998; Spielmann et al., 1999) , a compendium of 347 chemicals for which the IC 50 values for 3T3 and NHK cells using neutral red uptake have been measured and the oral rat or mouse LD 50 values are known, was used to standardize the procedures for qualifying any cytotoxicity test and to determine whether such a cytotoxicity test can use the RC Prediction Model (Halle, 1998; Spielmann et al., 1999) . Eleven reference chemicals from the RC are used for a cytotoxicity assay. These 11 chemicals were used in the second validation phase of the HALO Platform. However, rather than testing these chemicals on a single population from a single species, we utilized the multifunctionality and highthroughput capability of the procedure to study seven different lympho-hematopoietic populations from human and mouse bone marrow simultaneously. The results from this and a second study, which employed only human bone marrow to evaluate several different anticancer drugs, demonstrated a number of commonalities that could be brought together into a prediction paradigm for hemotoxicity testing. It should be emphasized that these predictions are based on our knowledge of the biology and physiology of the lympho-hematopoietic system. However, as far as we are aware, this is the first time that a systematic study of this kind has been performed and provides direct evidence that the effects of different compounds on stem and progenitor cells can be used to predict how the blood-forming system will respond and what the effects in the periphery will be.
The correlation produced by the IC 50 values of nine of the tested compounds with the LD 50 values provided by the Tables 1 and 2 ). The IC50 results are plotted against the oral rat or mouse LD50 to produce a linear regression showing both the 95% confidence and prediction limits. 
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Registry of Cytotoxicity validates the HALO Platform to be used as a cytotoxicity test. This, in turn, allows the RC Prediction Model to be applied to results produced by HALO. An important application of this is shown in Table 3 , where the IC values for several anticancer drugs have been used to calculate and predict clinical doses. In the last column of this table, clinical doses that have been used in the past or are actually used today for the treatment of different cancers are shown. In most cases, the estimated doses are similar to those actually used in the clinic. Another important observation is that many of the anticancer drugs tested are not employed for treatment of blood malignancies. As such, HALO, even though it is used to measure responses to the lympho-hematopoietic system, can be used to extrapolate results applicable to other systems, most notably, systems that exhibit continuous proliferation. This is because these systems have a similar organizational structure to that of the lympho-hematopoietic system comprising a stem cell, amplification and differentiation, maturation, and functional mature end cell compartment.
Finally, the ability to incorporate primary human hematopoietic tissue into a validated, predictive platform that can be used at all stages of drug development, but especially during early drug screening, cannot be underestimated. By incorporating HALO into the drug screening process, a valuable decision-making tool can be utilized that can save money, time, animals, but above all, provide increase efficacy and safety for the patient.
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